Earnings Call Summary | ADC Therapeutics(ADCT.US) Q1 2024 Earnings Conference
Earnings Call Summary | ADC Therapeutics(ADCT.US) Q1 2024 Earnings Conference
The following is a summary of the ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript:
以下是ADC Therapeutics SA（ADCT）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
ADC Therapeutics SA reported Q1 2024 revenue of $17.8 million, a 7% sequential increase over the previous quarter due to community and academic center growth.
The company reduced their operating expenses by 16% YoY on a non-GAAP basis via disciplined capital allocation strategy.
Their cash balance at the end of the first quarter was $234.3 million.
They priced an underwritten offering to raise $105 million, extending their cash runway to mid-2026, and thus increasing their financial flexibility.
ADC Therapeutics SA報告稱，由於社區和學術中心的增長，2024年第一季度收入爲1780萬美元，比上一季度連續增長7％。
該公司通過嚴格的資本配置策略，在非公認會計准則的基礎上將其運營支出同比減少了16％。
他們在第一季度末的現金餘額爲2.343億美元。
他們對承保發行進行了定價，以籌集1.05億美元，將現金流延長至2026年中期，從而提高了財務靈活性。
Business Progress:
業務進展：
In their LOTIS-7 study of ZYNLONTA, they cleared the final dosing cohort in both arms with no high cases or dose-limiting toxicities being reported.
The company initiated enrolment of pancreatic cancer patients for ADCT-601 while optimising the dose and schedule.
They are conducting a 50-patient study on MZL and the LOTIS-5 trial, completing the 'Part 2 dose expansion' stage, and expect to complete enrolment of roughly 20 patients in each dosing cohort by year-end.
Despite facing competition, their product ZYNLONTA is showing promising signs, particularly with regard to the safety profile.
在 ZYNLONTA 的 LOTIS-7 研究中，他們清除了兩組的最終給藥隊列，沒有報告任何高病例或劑量限制毒性。
該公司開始招募胰腺癌患者接種 ADCT-601，同時優化劑量和時間表。
他們正在對MZL和 LOTIS-5 試驗進行一項50名患者的研究，完成了 “第二部分劑量擴展” 階段，預計到年底將完成每個給藥隊列中約20名患者的入組。
儘管面臨競爭，但他們的產品ZYNLONTA仍顯示出令人鼓舞的跡象，尤其是在安全方面。
More details: ADC Therapeutics IR
更多詳情： ADC 療法 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。